Kaye Biotech Inc. had the following equity account balances at December $31,2022$:

On February $1,2023,5,700$ preferred shares were issued at $$8\mathrm{.}40$ each. The board of directors declared and paid the annual cash

dividend on the preferred shares on June $30,2023,$ and a $10\%$ common share dividend was declared and distributed on the same day

when the market price per common share was $$4\mathrm{.}55.$ On October $1,2023,21,400$ common shares were issued at $$4\mathrm{.}69$ each. Profit

earned during $2023$ was $$415,800.$

Required:

Using the information provided, prepare the statement of changes in equity for the year ended December $31,2023.($Amounts to be

deducted should be indicated by a minus sign.$)$Kaye Biotech Inc. had the following equity account balances at December $31,2022$:

Preferred shares, $$2\mathrm{.}80,$ non$-$cumulative,

Authorized: $21,400$ shares

Issued and outstanding: $5,700$ shares $ $39,900$

Common shares,

Authorized: Unlimited

Issued and outstanding: $88,500$ shares $299,541$

Retained earnings $43,400$

On February $1,2023,5,700$ preferred shares were issued at $$8\mathrm{.}40$ each. The board of directors declared and paid the annual cash dividend on the preferred shares on June $30,2023,$ and a $10\%$ common share dividend was declared and distributed on the same day when the market price per common share was $$4\mathrm{.}55.$ On October $1,2023,21,400$ common shares were issued at $$4\mathrm{.}69$ each. Profit earned during $2023$ was $$415,800.$

Required:

Using the information provided, prepare the statement of changes in equity for the year ended December $31,2023.$